Inventage Lab
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Inventage Lab develops drug delivery technology, systems that control how and how long a medicine is released inside the body after injection.
Its platforms serve pharmaceutical companies and biotechs that need long-acting injectable formulations, genetic medicines such as mRNA vaccines, and biologic drugs that it helps convert from intravenous to under-the-skin delivery. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company pursues revenue through a combination of licensing its platform technology to partners, co-developing drug candidates, and providing contract development and manufacturing services.
Summary is AI-generated and may contain errors · figures from DART filings
A named subsidiary, Curatis, holds dedicated GMP-certified manufacturing facilities for long-acting injectables and gene-therapy or mRNA vaccine production that underpin the contract manufacturing business.
Inventage Lab in five facts
What does Inventage Lab do?
Inventage Lab develops drug delivery technology, systems that control how and how long a medicine is released inside the body after injection.
Where is Inventage Lab listed and in which sector?
Inventage Lab (Korean name: 인벤티지랩) trades under KRX code 389470 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Inventage Lab?
Its market capitalisation was US$263.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Inventage Lab's latest annual revenue and operating profit?
For fiscal year 2025, Inventage Lab reported revenue of US$2.2M, an operating loss of US$21.4M and a net loss of US$12M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 64.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 19
- Investor relations (IR) meetingSep 15
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 22
- Material event report (decision to redeem own convertible bonds early)Capital raise · Jun 15
- [Amended] Material event report (rights offering)
Inventage Lab updated the terms of convertible bonds to raise US$35.4M, about 14.6% of its market value.
Capital raise · Mar 17 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Inventage Lab reported consolidated results for FY2025: revenue of US$1.96M (+64.8% year on year), an operating loss of US$18.9M and a net loss of US$10.6M.
Earnings · Mar 16 - Securities issuance results (voluntary)Capital raise · Mar 16
- Material event report (rights offering)
Inventage Lab disclosed convertible bonds to raise US$35.5M, about 14.6% of its market value.
Capital raise · Mar 9 - Decision to acquire shares/equity in another company (voluntary)
Inventage Lab disclosed an acquisition of Quratis, worth US$6.76M.
M&A · Mar 6 - Material event report (bonds with warrants)
Inventage Lab disclosed bonds with warrants to raise US$5.75M, about 2.4% of its market value.
Capital raise · Mar 6 - Material event report (convertible bonds)
Inventage Lab disclosed convertible bonds to raise US$25.2M, about 10.3% of its market value.
Capital raise · Mar 6 - Decision to acquire shares/equity in another company
Inventage Lab disclosed an acquisition of Quratis, worth US$9.46M.
M&A · Feb 26 - [Attachment amended] Material event report (decision to sell own convertible bonds)Capital raise · Jan 22
- Material event report (decision to sell own convertible bonds)Capital raise · Jan 22